Review for "Efficacy and safety of polyethylene glycol loxenatide ( PEX168 ) monotherapy in type 2 diabetes patients: a multicenter, randomized, double‐blind, placebo‐controlled, phase 3a clinical trial"

Author(s):  
Mikkel Agersnap
Sign in / Sign up

Export Citation Format

Share Document